Sign in to baba News

The Desk, the news read to you every hour, is part of News Plus.

or use an email code

By continuing you agree to the terms and privacy policy.

Keep the whole picture

News Plus opens the cross-newsroom layer — who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

By continuing you agree to the terms and privacy policy.

Welcome — one more step

News Plus opens the cross-newsroom layer — who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to save this article and find it on your phone.

or use an email code

By continuing you agree to the terms and privacy policy.

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

By continuing you agree to the terms and privacy policy.

Choose the alerts that matter to you

News Plus includes topic, person and story alerts, and your own coverage surge threshold.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal
See News Plus
Health · Full coverage

FDA Approves New ADHD Drug Simtriyo With Novel Mechanism, Experts Urge Caution

How 3 Israeli newsrooms covered this story — translated into English and compared side by side.

67% center
Center 2Right 1

By יעל אנקר

What happened

The FDA approved Simtriyo, a new ADHD drug with a unique serotonin-influencing mechanism, for patients aged six and above. Clinical trials showed symptom improvement, but experts urge caution pending long-term data and broader use. Simtriyo is not yet approved in Israel.

  • 01FDA approved Simtriyo, a new ADHD drug affecting serotonin, dopamine, and norepinephrine.
  • 02Clinical trials showed significant symptom improvement, some within the first week.
  • 03Common side effects include appetite loss, nausea, headaches, and insomnia.
  • 04Experts caution that long-term data is needed before declaring it superior to existing treatments.
  • 05Simtriyo is not yet approved for use in Israel and requires local regulatory review.
  • 06Specialists stress individualized ADHD treatment combining medical and behavioral approaches.

Summary translated & synthesized from the sources below by baba. Read each original for the full report.

Ask About This Story

Duki reads it, and every newsroom on the same story, then answers with sources.

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

By continuing you agree to the terms and privacy policy.

Keep the whole picture

News Plus opens the cross-newsroom layer — who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Live Terminal

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play
In this story
People
OrganizationsFDA
PlacesUnited States, Israel

Full coverage · 3 outlets

The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.

Now 14Right · HebrewAug 6, 2026
FDA Approves New ADHD Drug Simtriyo With Novel Mechanism, Experts Urge Caution
MakoCenter · HebrewAug 6, 2026
Experts Advise Caution and Holistic Approach for New ADHD Medication in Children
N12Center · HebrewAug 6, 2026
Experts Advise Caution and Holistic Approach for New ADHD Medication in Children